title: Position statement for isotretinoin.
authors.affiliation: agupta@execulink.com
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Charles W
authors.initials: CW
authors.lastname: Lynde
authors.forename: Yves
authors.initials: Y
authors.lastname: Poulin
authors.forename: Kevin
authors.initials: K
authors.lastname: Smith
authors.forename: Richard
authors.initials: R
authors.lastname: Lewis
authors.forename: Catherine
authors.initials: C
authors.lastname: Zip
mesh_terms: D002170:Canada; D032962:Consent Forms; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004346:Drug Information Services; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D020407:Internet; D015474:Isotretinoin / Q000627:therapeutic use*; D011247:Pregnancy; D011258:Pregnancy Tests; D012308:Risk Management; D014481:United States
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin